Maxwell Biomedical

1 known investors

MaxWell Biomedical develops a cardiac resynchronization therapy device (CRT-A) designed to restore both sinus rhythm and atrial mechanical function in patients with atrial fibrillation, particularly those with post-surgical AF or AF combined with heart failure. The device uses a physiology-guided, non-destructive approach as an alternative to ablation and pharmacologic treatments.